Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing
Teva Pharmaceutical Industries Limited
-(TEVA)
XNYS:TEVA
Teva Pharmaceutical Industries Ltd (TEVA) Q2 2021 Earnings Call Transcript
Teva Pharmaceutical Industries Ltd (NYSE: TEVA) Q2 2021 earnings call dated Jul. 28, 2021. Corporate Participants: Kevin C. Mannix -- Senior Vice President,
Earnings calendar for the week of July 26
After showing weakness at the beginning of the week, benchmark stock indexes made steady gains even as economic recovery gathered steam. On
Infographic: Teva Pharmaceuticals (TEVA) Q1 2021 earnings results
Teva Pharmaceuticals’ (NYSE: TEVA) reported first-quarter 2021 results today before the opening bell. The company dropped its revenue by 9% to $3.98
Teva Pharmaceuticals (TEVA) Q2 2020 earnings: Reaffirms FY20 outlook
Teva Pharmaceuticals (NYSE: TEVA) beat Q2 earnings estimates, but fell short of Street's revenue targets. The drug manufacturer reported adjusted EPS of
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q1 2020 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (TEVA) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Kevin C. Mannix -- Senior Vice President, Investor Relations
Infographic: Teva Pharmaceuticals (TEVA) Q1 2020 earnings results
Teva Pharmaceuticals' (NYSE: TEVA) first quarter 2020 results beat consensus estimates. The drugmaker reported adjusted earnings of $0.76 per share on revenue
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Call Transcript
Teva Pharmaceutical Industries Limited (NYSE: TEVA) Q4 2019 Earnings Conference Call February 12, 2020 Corporate participants: Kevin C. Mannix -- Senior Vice President, Investor
It’s time to see Teva Pharmaceuticals (TEVA) from a different perspective
Shares of Teva Pharmaceuticals (NYSE: TEVA) fell to a new low this month as markets across the world continued to be battered
Teva Pharmaceutical (TEVA) swings to profit in Q4, beats estimates
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) swung to a profit in the fourth quarter of 2019 from a loss last year, helped
Teva Q3 profit misses estimates, tightens FY19 forecast
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) reported a wider loss in the third quarter of 2019 as generic competition hurt Copaxone revenue
What the future holds for generic drug industry
The size of the generic drug market in the US is so large that about 90% of all prescription medicines sold last
What’s in store for top pharma stocks this year
The stocks of leading pharmaceutical firms shifted to growth mode this year after winding up 2018 on a low note, in line
Looming opioid epidemic calls for stricter drug regulation
Though the healthcare industry is slowly waking up to the hazards of opioid-based prescription drugs, their sale continues unabated across all markets,
Teva Pharma sinks on Q1 revenue miss amid generic competition; earnings beat
Drugmaker Teva Pharmaceutical (NYSE: TEVA) reported a decline in first-quarter adjusted earnings, owing to a 15% fall in revenues as the company
Earnings preview: New product launches in focus as Teva gets ready for Q1 report
Teva Pharmaceutical (NYSE: TEVA) has long endued uncertainties in business even as the generic drug maker continued its efforts to tackle high
Axsome Therapeutics stock climbs to 34-month high
After the slump on weak quarterly results, investors turned positive on Axsome Therapeutics (AXSM) stock, which climbed to the 34-month high of
Earnings: Teva Pharma shrinks Q4 losses, but revenue falls
Teva Pharma (TEVA) posted its fourth-quarter 2018 before the opening bell on Feb. 13. The generic drugmaker saw revenue slip 16% to $4.56
Earnings Preview: Positive sentiment around Teva
Teva Pharmaceutical Industries Ltd. (TEVA) is scheduled to report fourth-quarter 2018 earnings results on Wednesday, February 13, before market open. Wall Street
Teva’s shares soar on better-than-expected Q3 results and higher guidance
Teva Pharmaceutical Industries Ltd. (TEVA) saw its stock gain over 6.8% during premarket hours on Thursday after the company surpassed expectations on